

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2024/254005 A1

(43) International Publication Date
12 December 2024 (12.12.2024)

(51) International Patent Classification:

A61K 31/565 (2006.01) *A61P 25/24* (2006.01)
A61K 31/57 (2006.01) *A61P 25/28* (2006.01)
A61K 9/00 (2006.01)

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/US2024/032273

(22) International Filing Date:

03 June 2024 (03.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/470,933 04 June 2023 (04.06.2023) US

(71) Applicant: **VISTAGEN THERAPEUTICS, INC.**

[US/US]; 343 Allerton Avenue, South San Francisco, CA
94090 (US).

(72) Inventors: **MONTI, Louis**; c/o Vistagen Therapeutics,

Inc., 343 Allerton Avenue, South San Francisco, CA 94560

(US). **ADLER, Reid, G.**; c/o Vistagen Therapeutics, Inc.,

343 Allerton Avenue, South San Francisco, CA 94560 (US).

BAKER, Ross, A.; c/o Vistagen Therapeutics, Inc., 343

Allerton Avenue, South San Francisco, CA 94560 (US).

(74) Agent: **NGUYEN, Sam, L.** et al.; HDC Intellectual Proper-

ty Law, LLP, 24781 Anchor Lantern, Dana Point, CA 92629

(US).

(81) Designated States (*unless otherwise indicated, for every*

kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,

KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,

ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every*

kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,

GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: 1,3,5(10),16-ESTRATETRAEN-3-YL ACETATE FOR USE IN IMPROVING PSYCHOMOTOR OR COGNITIVE PERFORMANCE

(57) Abstract: Intranasal administration of 1,3, 5(10), 16-estratetraen-3-yl acetate is useful in improving psychomotor and/or cognitive performance in mentally fatigued persons.

WO 2024/254005 A1